GoMeyra Launches Real-Time, Cloud-Based LIMS for Medical Laboratories to Process Same-Day Lab Test Results

Revolutionary software program features first-of-its-kind apps to track test results allowing for quicker returns to work, school and travel, and increased peace of mind

GoMeyra, an innovative new software company dedicated to providing revolutionary tech solutions for medical laboratories, announced today the launch of a customizable cloud-based lab information management system – GoMeyra LIMS.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005321/en/

GoMeyra LIMS was developed as a solution to alleviate bottlenecks and increase efficiency challenges inherent in laboratory workflows. (Photo: Business Wire)

Recognizing the tremendous pressure labs are experiencing to turn around COVID-19 test results, GoMeyra LIMS was specifically designed and developed as a solution to alleviate bottlenecks and increase efficiency challenges inherent in laboratory workflows. By bringing together the bioinformatic expertise of world-class scientists with enterprise-level software engineers, GoMeyra is an unparalleled digital solution for medical laboratories.

The result – this groundbreaking LIMS platform is transforming the testing industry by providing unprecedented processing times. Currently the end-to-end processing platform for dozens of labs and medical practices in the U.S., GoMeyra LIMS is making an immediate impact on productivity – tripling daily capacity and empowering labs to provide same-day, direct-to-patient results reporting. Utilized by labs that service Hollywood film & TV studios, major casinos, pro sports franchises and enterprise-level organizations that employ thousands of Americans, GoMeyra LIMS is enabling the public to return to work, school and normal activities quicker than any other lab solution since the start of the pandemic.

“When the pandemic started, as I continued to see COVID-19 rates increase, it became clear that a solution to the systemic problem of delayed test results caused by labs’ lack of preparedness was desperately needed. I knew this was a perfect way for me to help in the crisis, and channeled my 20 years

Intel inks agreement with Sandia National Laboratories to explore neuromorphic computing

As a part of the U.S. Department of Energy’s Advanced Scientific Computing Research program, Intel today inked a three-year agreement with Sandia National Laboratories to explore the value of neuromorphic computing for scaled-up AI problems. Sandia will kick off its work using the 50-million-neuron Loihi-based system recently delivered to its facility in Albuquerque, New Mexico. As the collaboration progresses, Intel says the labs will receive systems built on the company’s next-generation neuromorphic architecture.

Along with Intel, researchers at IBM, HP, MIT, Purdue, and Stanford hope to leverage neuromorphic computing — circuits that mimic the nervous system’s biology — to develop supercomputers 1,000 times more powerful than any today. Chips like Loihi excel at constraint satisfaction problems, which require evaluating a large number of potential solutions to identify the one or few that satisfy specific constraints. They’ve also been shown to rapidly identify the shortest paths in graphs and perform approximate image searches, as well as mathematically optimizing specific objectives over time in real-world optimization problems.

Intel’s 14-nanometer Loihi chip contains over 2 billion transistors, 130,000 artificial neurons, and 130 million synapses. Uniquely, the chip features a programmable microcode engine for on-die training of asynchronous spiking neural networks (SNNs), or AI models that incorporate time into their operating model such that the components of the model don’t process input data simultaneously. Loihi processes information up to 1,000 times faster and 10,000 more efficiently than traditional processors, and it can solve certain types of optimization problems with gains in speed and energy efficiency greater than three orders of magnitude, according to Intel. Moreover, Loihi maintains real-time performance results and uses only 30% more power when scaled up 50 times, whereas traditional hardware uses 500% more power to do the same.

Intel and Sandia hope to apply neuromorphic computing to workloads in scientific

Analysts Reiterate Overweight Rating on Abbott Laboratories following European Approval of Freestyle Libre 3

On Monday, J.P. Morgan and Morgan Stanley reiterated their Overweight ratings on Abbott Laboratories (ABT). The company’s newest continuous glucose monitor (CGM), the Freestyle Libre 3, recently received a CE mark of approval. The system has shown to be a major evolutionary improvement over the current Libre 2 which leads analysts to believe that there are multiple long-term growth opportunities for Abbott.

The next-gen Libre CGM, Libre 3 will leverage Bluetooth technology to have continuous, real-time glucose readings automatically delivered to your smartphone every-minute (vs user scanning required in the past) allowing for unsurpassed 14-day accuracy and a ~70% size reduction from the Libre 1 & 2, becoming the world’s smallest and thinnest sensor.

The FreeStyle Libre 3 system was designed to fit perfectly into people’s everyday lives, allowing users to check their glucose as often as they like by just looking on their phones. This innovation allows the users to live a more comfortable life and gain a deeper understanding of their glucose levels with the real-time data given by the smartphone. The cost of the FreeStyle Libre 3 will also be the same as previous generations of the device.

The Senior Vice President of Diabetes Care for Abbott Laboratories mentioned, “Abbott won’t stop innovating when there’s room to raise the bar. We’ve done that again with FreeStyle Libre 3, the smallest sensor that delivers life-changing benefits and best-in-class accuracy,”.

The transition from Abbott’s current system to its next-gen Libre CGM, Libre 3, shouldn’t require any extra hassle. The Libre 3 system will have identical algorithms and chemistry compared to the Libre 2.

As highlighted by the analysts at JPMorgan, the ”Libre 3 essentially adds three things: (1) it shrinks Libre’s already small footprint to the size of two stacked pennies. The approval is for wear on the arm,